Government of Saskatchewan

October 1, 2023
Bulletin #233
ISSN 1923-0761

SASKATCHEWAN FORMULARY BULLETIN
Update to the 62nd Edition of the Saskatchewan Formulary

Exception Drug Status (EDS) Benefit According to the Following Criteria:

- **romosozumab, pre-filled syringe, 105mg/1.17mL (syr) (Evenity)**

  For the treatment of osteoporosis in postmenopausal women:
  - With a history of osteoporotic fracture and at high risk for future fracture (defined as a 10-year fracture risk ≥ 20% as defined by the FRAX tool), and
  - Who are treatment naïve to osteoporosis medications and are not receiving concurrent osteoporosis medications except for calcium and/or vitamin D.

  Treatment approval will be to a maximum of 12 months.

- **somatropin, pre-filled pen, 5mg/1.5mL, 10mg/1.5mL, 15mg/1.5mL (pen) (Norditropin FlexPro)**

  For treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

Saskatchewan Biosimilars Initiative Update: Humalog® (insulin lispro)

Effective October 1, 2023, the Saskatchewan Biosimilars Initiative transition period for Humalog® (insulin lispro) will continue. The transition was announced last year and was paused in December 2022. Supply of the biosimilar (Admelog®) has now stabilized, and patients can access the biosimilar.

Coverage of **Humalog® 100 units/mL** will be available on the Saskatchewan Formulary until **March 31, 2024**. Patients will need to use a biosimilar version in order to maintain Saskatchewan Drug Plan coverage of their treatment after this date.

Please note: coverage of Humalog® 200 units/mL is available for patients who need a higher concentration formula, as there is no equivalent biosimilar format at this time.

Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert St
REGINA SK S4S 6X6
306-787-3317 or 1-800-667-7581